Stock events for Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics' stock has been impacted by several events over the past six months. Positive Phase 1b results for NMRA-511 in Alzheimer's disease agitation and the initiation of a Phase 1 study of NMRA-898 for neuropsychiatric indications were announced. The company also announced positive preclinical obesity data for NMRA-215 and reported its Q3 2025 financial results, indicating a cash runway into 2027. Analyst coverage and upgrades from William Blair and Leerink Partners were noted. Insider selling activity occurred, and the stock price experienced a significant increase.
Demand Seasonality affecting Neumora Therapeutics, Inc.’s stock price
Neumora Therapeutics does not experience traditional demand seasonality for its products and services. Demand for its pipeline products will primarily be driven by the prevalence of the targeted diseases and the efficacy and safety profile of its therapies.
Overview of Neumora Therapeutics, Inc.’s business
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for brain diseases, operating within the Healthcare sector and Biopharmaceutical industry. The company aims to redefine neuroscience drug development with next-generation therapies for neurological and psychiatric disorders. Its pipeline includes Navacaprant for major depressive disorder, NMRA-511 for agitation associated with dementia due to Alzheimer's disease, NMRA-266 and NMRA-898 for schizophrenia, NMRA-NMDA for schizophrenia, NMRA-CK1d for amyotrophic lateral sclerosis, NMRA-NLRP3 for neurodegenerative conditions and obesity, and NMRA-GCase for Parkinson's disease.
NMRA’s Geographic footprint
Neumora Therapeutics is headquartered in Watertown, Massachusetts, with research and development primarily in the greater Boston area. The company plans to expand collaborations and strategic partnerships both within the United States and internationally.
NMRA Corporate Image Assessment
Neumora Therapeutics' brand reputation has been influenced by positive clinical trial results and a class action lawsuit. Positive Phase 1b results for NMRA-511 and analyst endorsements have contributed positively. A class action lawsuit alleging misrepresentations in the company's IPO offering documents could negatively impact the company's reputation.
Ownership
Neumora Therapeutics has a mixed ownership structure. Institutional investors hold approximately 37.66% of the stock, with major shareholders including Softbank Group Corp and Vanguard Group Inc. Company insiders own approximately 97.99% of the stock, with Kristina Burow being the largest individual shareholder. Retail investors hold a smaller percentage of the company's stock.
